We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma.
- Authors
Yousef, Abdelrahman; Yousef, Mahmoud; Chowdhury, Saikat; Abdilleh, Kawther; Knafl, Mark; Edelkamp, Paul; Alfaro-Munoz, Kristin; Chacko, Ray; Peterson, Jennifer; Smaglo, Brandon G.; Wolff, Robert A.; Pant, Shubham; Lee, Michael S.; Willis, Jason; Overman, Michael; Doss, Sudheer; Matrisian, Lynn; Hurd, Mark W.; Snyder, Rebecca; Katz, Matthew H. G.
- Abstract
The relevance of KRAS mutation alleles to clinical outcome remains inconclusive in pancreatic adenocarcinoma (PDAC). We conducted a retrospective study of 803 patients with PDAC (42% with metastatic disease) at MD Anderson Cancer Center. Overall survival (OS) analysis demonstrated that KRAS mutation status and subtypes were prognostic (p < 0.001). Relative to patients with KRAS wildtype tumors (median OS 38 months), patients with KRASG12R had a similar OS (median 34 months), while patients with KRASQ61 and KRASG12D mutated tumors had shorter OS (median 20 months [HR: 1.9, 95% CI 1.2–3.0, p = 0.006] and 22 months [HR: 1.7, 95% CI 1.3–2.3, p < 0.001], respectively). There was enrichment of KRASG12D mutation in metastatic tumors (34% vs 24%, OR: 1.7, 95% CI 1.2–2.4, p = 0.001) and enrichment of KRASG12R in well and moderately differentiated tumors (14% vs 9%, OR: 1.7, 95% CI 1.05–2.99, p = 0.04). Similar findings were observed in the external validation cohort (PanCAN's Know Your Tumor® dataset, n = 408).
- Subjects
UNIVERSITY of Texas M.D. Anderson Cancer Center; PANCREATIC duct; RAS oncogenes; TREATMENT effectiveness; PANCREATIC enzymes; GENETIC mutation; ADENOCARCINOMA; PANCREATIC intraepithelial neoplasia
- Publication
NPJ Precision Oncology, 2024, Vol 8, Issue 1, p1
- ISSN
2397-768X
- Publication type
Article
- DOI
10.1038/s41698-024-00505-0